Moreover, the investigators further elucidated that the tumor-free surviving treatment subjects managed to develop protective immune reactions against ovarian cancer (which include memory CD8-positive T cell and CD4-positive T cell reactions) since they rejected another ovarian tumor development with the ovarian cancer cells, 225 days following the initial time of tumor establishment (123). The gene discussed is CD8A; the disease is ovarian cancer.